5 Most Profitable Small Cap Stocks to Buy

4. CorMedix Inc. (NASDAQ:CRMD)

Net Profit Margin: 45.25%

Operating Margin: 49.96%

On May 14, 2026, CorMedix Inc. (NASDAQ:CRMD) reported Q1 net revenue of $127.4 million and net income of $38.6 million with adjusted EBITDA of $70.0 million. The firm said DefenCath contributed $97.5 million in revenue with higher outpatient dialysis utilization and a $9.0 million favorable estimate change. The acquired Melinta portfolio added $29.9 million.

The company raised its 2026 guidance, projecting revenue between $325 million and $345 million and adjusted EBITDA to $115 million-$135 million. The corporation reported cash and short-term investments of $178.1 million as of March 31, 2026.

Chairman and CEO Joseph Todisco said CorMedix entered the year with “strong momentum” and that DefenCath “continues to exceed expectations” despite pending TDAPA expiration. He also noted progress in late-stage programs, including REZZAYO, with the company preparing an FDA submission in the second half of 2026. It targets a potential expanded launch in 2027.

CorMedix Inc. (NASDAQ:CRMD) is a pharmaceutical and medical device firm that makes and markets therapeutic solutions for the prevention and treatment of diseases and conditions.